- Conditions
- Multiple Myeloma
- Interventions
- CI-994
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2003
- U.S. locations
- 1
- States / cities
- Tampa, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 577–600
of 6,312
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Head and Neck Cancer
- Interventions
- cetuximab, conventional surgery, radiation therapy
- Biological · Procedure · Radiation
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 3
- States / cities
- Lakewood, New Jersey • Long Branch, New Jersey • Somerville, New Jersey
- Conditions
- Advanced Cancers
- Interventions
- Questionnaire
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- nab-sirolimus
- Drug
- Lead sponsor
- Aadi Bioscience, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • New Orleans, Louisiana • Las Vegas, Nevada + 3 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Ixabepilone, Carboplatin, Bevacizumab
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 13
- States / cities
- Fort Myers, Florida • Gainesville, Florida • Terre Haute, Indiana + 10 more
- Conditions
- Malignant Mesothelioma
- Interventions
- epirubicin hydrochloride, gemcitabine hydrochloride
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 24
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 21 more
- Conditions
- Advanced Solid Tumor, Metastatic Breast Cancer
- Interventions
- Abraxane, ORIN1001
- Drug
- Lead sponsor
- Orinove, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 20
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Burbank, California + 16 more
- Conditions
- Renal Cancer
- Interventions
- Ipilimumab, Nivolumab
- Drug
- Lead sponsor
- Toni Choueiri, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 8
- States / cities
- La Jolla, California • Chicago, Illinois • Boston, Massachusetts + 4 more
- Conditions
- Hepatocellular Carcinoma Recurrent
- Interventions
- TheraBionic P1
- Device
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 8
- States / cities
- Ann Arbor, Michigan • Bay City, Michigan • Detroit, Michigan + 5 more
- Conditions
- Breast Cancer
- Interventions
- Magnetic Resonance Imaging (MRI), Magnetic Resonance Spectroscopy (MRS)
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Brain Metastases, Generalized Malignancy, Primary, Brain Lesions
- Interventions
- TPI 287, Fractionated Stereotactic Radiotherapy (FSRT)
- Drug · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Clear-cell Metastatic Renal Cell Carcinoma
- Interventions
- Everolimus, MLN0128, MLN1117
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Venice, Florida • West Palm Beach, Florida + 4 more
- Conditions
- Parkinson's Disease (PD)
- Interventions
- NUSHU shoe
- Device
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Breast Cancer, Advanced Prostate Cancer, Advanced Lung Cancer, Advanced Colorectal Carcinoma, Advanced Colorectal Adenocarcinoma
- Interventions
- ENGAGE, Supportive Care
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Urothelial Cancer
- Interventions
- Gemcitabine, Cisplatin, Sunitinib
- Drug
- Lead sponsor
- US Oncology Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 48
- States / cities
- Tucson, Arizona • Miami, Florida • New Port Richey, Florida + 42 more
- Conditions
- Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Cancer, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastric Carcinoma, Unresectable Esophageal Cancer, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Carcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
- Interventions
- AgenT-797, Botensilimab, Balstilimab, Ramucirumab, Paclitaxel
- Biological · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Advanced Endometrial Cancer
- Interventions
- Pembrolizumab, Acasunlimab
- Biological
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- Orlando, Florida • New Brunswick, New Jersey
- Conditions
- Stomach Neoplasms, Esophageal Neoplasms
- Interventions
- Irinotecan, Trastuzumab, Oxaliplatin, Leucovorin, Fluorouracil
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- ExAblate 2100
- Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Interventions
- Akt Inhibitor MK2206, Hydroxychloroquine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Solid Tumor
- Interventions
- LZM009,recombinant humanized anti-PD-1 monoclonal antibody for injection
- Biological
- Lead sponsor
- Livzon Pharmaceutical Group Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Grand Rapids, Michigan • San Antonio, Texas
- Conditions
- Tri-specific Killer Engager, Solid Tumor, Advanced Solid Tumor
- Interventions
- GTB-5550
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Breast Cancer
- Interventions
- Dasatinib
- Drug
- Lead sponsor
- Baylor Breast Care Center
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- KRAS P.G12C
- Interventions
- D3S-001, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Cetuximab
- Drug
- Lead sponsor
- D3 Bio (Wuxi) Co., Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 442 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Orange, California • Palo Alto, California • Denver, Colorado + 4 more